Omkar Speciality Chemicals LtdQ4 FY17Chemicals & Petrochemicals

Omkar Speciality Chemicals Ltd

Q4 FY17 Earnings Call Analysis

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Order

N/A

Capex

0 of 4 growth signals are positive — mixed outlook.

Revenue guidance

Category 2

→The company is guiding for around 25% year-on-year growth in Pharma Intermediates as well as APIs on a consolidated basis. (Page 11)
→The new API manufacturing Unit #5 in Chiplun is expected to start production in Q1 FY17 with gradual scale-up, reaching good utilization and sales from Q2 FY17 onwards, focusing on Vitamin C and Folic Acid with healthy margins and significant growth opportunities. (Pages 6,11)
→About 20% to 25% of overall revenue is projected to come from Iodine Derivatives over the next two years, though the company is defocusing this segment due to lower margins. (Page 10)
→The focus will be more on Specialty Intermediates, Resolving agents, and Veterinary APIs which are expected to show steep growth and better EBITDA margins. (Page 10)
→The business model aims to maintain consistent EBITDA margins of around 18-19% despite raw material and forex fluctuations. (Page 6)

Category 3

→Omkar Speciality Chemicals Ltd expects around 25% year-on-year growth in Pharma Intermediates and APIs (consolidated across segments).
→EBITDA margins are consistently expected around 18-19%, with some segments like Vitamin C projected at 18-20%.
→The new API manufacturing Unit #5 at Chiplun (starting Q1 FY17) will gradually scale up, contributing positively to sales and profits from Q2 FY17 onwards.
→Focus is shifting towards higher margin Specialty Intermediates and APIs, reducing reliance on low-margin Iodine derivatives, which will constitute 20-25% of revenues in the next two years.
→Working capital and operational efficiencies are improving, supporting better cash flows and margins.
→No major CAPEX planned, barring acquisitions; expected small CAPEX (~Rs. 10-12 crores) to enhance current capacity.
→Stable EBITDA and profit growth expected despite market volatilities like forex and raw material cost fluctuations.

Get access to all 5 sections — revenue, margin, fundraise, orderbook, and capex — for Omkar Speciality Chemicals Ltd and 1,400+ other companies.

→No major new fundraising through debt or equity is planned currently.
→The company does not anticipate big CAPEX in the next two years except for minor debottlenecking and capitalizing existing work-in-progress (around Rs. 10 to 12 crores).
→Any significant fundraising may only occur if an acquisition opportunity arises which is remunerative to the company.
→Routine business growth will be supported by existing capacities and current financial resources without additional major debt or equity infusion.

→Omkar Speciality Chemicals does not maintain a traditional order book.
→They operate on quarterly forecasts provided by their customers.
→Orders flow continuously based on these forecasts.
→The quarterly forecast is usually accurate with only a 10-15% variance.
→Customers are mainly reputed MNCs like Glaxo, Gilead Life, Abbott, Johnson & Johnson, and BASF.
→The forecasts provide guidance on expected sales volumes for the quarter.
→This system gives the company confidence in projecting business for their Intermediates segment.
→For APIs, demand is driven by customer product development and launch timelines.
→The plant's first phase utilization and orders are expected to scale up gradually after commissioning in Q1 FY17.

→No major CAPEX planned in the next two years.
→Only debottlenecking CAPEX and capital work-in-progress capitalization expected, amounting to around Rs. 10 to 12 crores.
→Existing CAPEX is sufficient to support the current growth rate for the next two years.
→New CAPEX might arise only in case of an acquisition or an unforeseen remunerative opportunity.
→Company is considering acquisition in the formulations space but nothing concrete or on the table currently.

How does Omkar Speciality Chemicals Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Omkar Speciality Chemicals Ltd

Rev 2Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Omkar Speciality Chemicals Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.